Tesamorelin (10mg)
GHRH Analog
Tesamorelin is a synthetic GHRH analog specifically targeting visceral adipose tissue—the harmful deep belly fat linked to metabolic disease. FDA-studied for reducing abdominal fat accumulation, Tesamorelin offers precise metabolic benefits through natural growth hormone pathways.
The Science
What is Tesamorelin?
Tesamorelin is a synthetic analog of human growth hormone-releasing hormone (GHRH), consisting of 44 amino acids with enhanced stability. It binds to GHRH receptors in the pituitary gland to stimulate natural growth hormone production—but with a unique focus on visceral fat metabolism.
Unlike direct growth hormone administration, Tesamorelin works through the subject’s own regulatory pathways, maintaining physiologic GH pulsatility.
Licensed investigators leverage its targeted mechanism for research subjects struggling with abdominal adiposity despite diet and exercise efforts.
Laboratory Observations
Key Observed Effects of Tesamorelin (10mg)
Visceral Fat Reduction
Clinical trials demonstrated up to 15% reduction in visceral adipose tissue—targeting the dangerous deep abdominal fat linked to cardiovascular disease and metabolic syndrome.
Metabolic Improvement
Reducing visceral fat improves insulin sensitivity, glucose metabolism, and lipid profiles—addressing key markers of metabolic health and disease risk.
Body Composition
Supports lean muscle preservation while specifically targeting abdominal fat, improving waist-to-hip ratio and overall body composition without generalized weight loss.
Cardiovascular Benefits
Visceral fat reduction correlates with decreased cardiovascular risk markers, improved arterial function, and reduced inflammatory cytokines associated with heart disease.
FDA-Studied Efficacy
Backed by rigorous clinical trials and FDA approval for lipodystrophy, Tesamorelin has a well-documented safety profile and proven efficacy in targeting visceral fat.
Natural GH Pathway
Works through the subject’s own GHRH receptors to stimulate physiologic growth hormone release—avoiding the risks of direct GH administration.
Mechanism of Action
Targeted Visceral Fat Reduction
Tesamorelin activates natural GHRH receptors to stimulate pulsatile growth hormone release, which specifically enhances lipolysis in visceral adipose tissue while maintaining metabolic balance.
GHRH Receptor Binding
Binds to pituitary GHRH receptors with high affinity, triggering the natural cascade of growth hormone synthesis and secretion through physiologic pathways.
Growth Hormone Release
Stimulates pulsatile GH secretion that mimics natural patterns, increasing serum growth hormone and subsequently IGF-1 levels in a controlled manner.
Visceral Fat Mobilization
Enhanced GH/IGF-1 axis selectively promotes lipolysis in visceral adipose tissue—reducing dangerous abdominal fat that surrounds internal organs.
FAQ
Frequently Asked Questions
What makes Tesamorelin different from other peptides?+
Tesamorelin is unique in its FDA-studied, specific action on visceral adipose tissue—the dangerous deep abdominal fat. Unlike general fat loss compounds, it targets the metabolically harmful fat surrounding organs, with clinical trials demonstrating average 15% VAT reduction. It’s a GHRH analog working through natural pathways rather than direct GH administration.
Research-Only Notice
Tesamorelin (10mg) is categorized by the FDA as for research-purposes-only. It is not intended for human consumption, diagnosis, treatment, cure, or prevention of any disease. The information above summarizes effects observed in laboratory studies to date and is provided strictly for scientific and educational reference.